{"protocolSection":{"identificationModule":{"nctId":"NCT03887780","orgStudyIdInfo":{"id":"20387"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)","officialTitle":"A Real-World, Prospective, Observational Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto®) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)","acronym":"XARIN"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-10-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-02-29","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-04-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-03-21","studyFirstSubmitQcDate":"2019-03-21","studyFirstPostDateStruct":{"date":"2019-03-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-17","lastUpdatePostDateStruct":{"date":"2024-01-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under real-life conditions.\n\nThe study will be conducted in routine clinical practice settings. Approximately 1000 patients from India will be enrolled in this study. Patients will be observed for maximum period of 12 months after the start of Xarelto treatment or until it is no longer possible (e.g. lost to follow-up, death, withdrawal) before the end of the observation period.\n\nThe decision by the investigator to start with of Xarelto must be independent of the inclusion of a patient to the study."},"conditionsModule":{"conditions":["Non-valvular Atrial Fibrillation (NVAF)"],"keywords":["Stroke;","Systemic embolism"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":504,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment","description":"Rivaroxaban treatment-naïve patients, at least 18 years of age and presenting with NVAF will be considered eligible for participation in this study only after the decision to treat with rivaroxaban has been made by the treating physician.","interventionNames":["Drug: Rivaroxaban (Xarelto,Bay 59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto,Bay 59-7939)","description":"15 mg and 20 mg (OD)","armGroupLabels":["Treatment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of major bleeding events","description":"Major bleeding events include:\n\n* Fatal bleeding\n* Symptomatic bleeding in a critical area or organ\n* Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.\n\n  * Hemoglobin level; or\n  * Need for transfusion of packed red blood cells or whole blood.","timeFrame":"Up to 18 months"},{"measure":"Incidence of treatment-emergent AEs","timeFrame":"Up to 18 months"},{"measure":"Incidence of treatment-emergent SAEs","timeFrame":"Up to 18 months"},{"measure":"Incidence of all-cause death","description":"Deaths will be adjudicated as either vascular (e.g., due to stroke, embolism, myocardial infarction, or arrhythmia) or non-vascular (e.g., malignancy or infection).","timeFrame":"Up to 18 months"}],"secondaryOutcomes":[{"measure":"Incidence of symptomatic thromboembolic events","description":"The date of thromboembolic events, manner in which thromboembolic events were managed in the routine practice setting, and their outcomes will be recorded.\n\nThe thromboembolic events include:\n\n* Stroke and transient ischemic attack (TIA)\n* Systemic embolism\n* Myocardial infarction","timeFrame":"Up to 18 months"},{"measure":"Non-major bleeding events","description":"The date of non-major bleeding events, treatment approaches employed during non-major bleeding events, and the associated outcomes will be collected.","timeFrame":"Up to 18 months"},{"measure":"AE rates in the different NVAF risk factor categories","description":"Rates of AEs across patients with different baseline risk profiles for stroke or bleeding calculated using Congestive heart failure, Hypertension, Age, Diabetes mellitus, Stroke(CHADS2), Vascular disease, Age, Sex category (CHA2DS2-VASc), or Hypertension, Abnormal liver/renal function, Stroke history, Bleeding predisposition, Labile international normalized ratios, Elderly, Drug/alcohol usage (HAS-BLED).","timeFrame":"Up to 18 months"},{"measure":"SAE rates in the different NVAF risk factor categories","description":"Rates of SAEs across patients with different baseline risk profiles for stroke or bleeding calculated using Congestive heart failure, Hypertension, Age, Diabetes mellitus, Stroke (CHADS2), Vascular disease, Age, Sex category (CHA2DS2-VASc), or Hypertension, Abnormal liver/renal function, Stroke history, Bleeding predisposition, Labile international normalized ratios, Elderly, Drug/alcohol usage (HAS-BLED).","timeFrame":"Up to 18 months"},{"measure":"Treatment persistence with rivaroxaban","description":"Treatment persistence with rivaroxaban therapy will be defined as the absence of a gap of \\>60 days between two doses of rivaroxaban, without any switch to alternative anticoagulant. Reasons for any switch from or interruption of rivaroxaban therapy during the observation period will be collected and summarized.","timeFrame":"Up to 18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient should be an adult female or male, ≥18 years of age;\n* Patient should be diagnosed with NVAF and initiated with rivaroxaban treatment for prevention of stroke or systemic embolism per investigator's routine treatment practice;\n* Patient should not have received rivaroxaban in the past;\n* Patient/patient's legally acceptable representative should be willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Patient has contraindications to receive rivaroxaban therapy according to local prescribing information;\n* Patient is receiving anticoagulant therapy for indication other than NVAF and that needs to be continued as per discretion of treating physician;\n* Patient is participating in an investigational program with interventions outside of routine clinical practice.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Female and male patients ≥18 years of age with a diagnosis of NVAF will be enrolled only after the decision for treatment with rivaroxaban has been made by the investigator.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Batra Heart Centre","city":"Delhi","zip":"110062","country":"India","geoPoint":{"lat":28.65195,"lon":77.23149}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Click here for access to information about Bayer's transparency standards and Bayer studies.","url":"https://clinicaltrials.bayer.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.\n\nInterested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000004617","term":"Embolism"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}